Industry – Page 9 – Swanson Reed | Specialist R&D Tax Advisors

Fueling Innovation: iVEAcare Raises $27.5M to Advance Neuromodulation Therapy

iVEAcare, Inc., a pioneer in neuromodulation technology, has announced the successful close of a $27.5 million Series A financing round. Led by Vensana Capital, with participation from Treo Ventures, Hatteras Venture Partners, and an undisclosed strategic partner, this funding marks a significant milestone for the Minneapolis-based medical device company.

The company, the third spin-off from NuXcel, a renowned medical device accelerator, is dedicated to developing and commercializing next-generation neuromodulation technologies for treating chronic diseases. With this substantial investment, iVEAcare aims to propel its innovative neuromodulation therapy into the forefront of medical advancement.

Alongside the funding announcement, iVEAcare has appointed Todd Kerkow as President and CEO. With nearly three decades of experience in the medical device industry, including stints at Guidant, Cameron Health, Boston Scientific, and Cardionomic, Kerkow brings a wealth of expertise to lead the company forward.

Expressing excitement about the future, Kerkow emphasized the importance of the experienced investor group supporting iVEAcare. He envisions this Series A financing as a pivotal step towards delivering innovative neuromodulation therapy to patients and clinicians alike.

Amrinder Singh and Kirk Nielsen of Vensana Capital echoed Kerkow’s sentiments, highlighting the significance of neuromodulation as a frontier in medicine. They see iVEAcare’s technology as a potential best-in-class therapy with the power to impact countless patients positively.

With strong support from seasoned investors and a dedicated team at the helm, iVEAcare is poised to revolutionize neuromodulation therapy and make significant strides in improving patient outcomes.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

EarliTec Diagnostics Secures $21.5M for Groundbreaking Autism Diagnostic Tool

In a groundbreaking development for autism diagnostics, EarliTec Diagnostics, Inc. has secured $21.5 million in Series B financing. Led by Nexus NeuroTech Ventures and Venture Investors Health Fund, this funding will propel the commercialization of the EarliPoint Evaluation and drive further product development efforts.

EarliTec’s EarliPoint Evaluation is a first-of-its-kind tool designed to assist clinicians in diagnosing and assessing autism in toddlers aged 16-to-30 months. Utilizing Social-Visual Engagement technology, it tracks a child’s moment-by-moment looking behavior, providing objective measurements crucial for early identification of autism.

Despite autism’s prevalence, limited access to diagnosis and treatment options poses challenges for families. EarliPoint addresses this gap by offering a personalized, quantifiable, and objective diagnostic tool, empowering clinicians to deliver timely and personalized care.

The Series B funding will further EarliTec’s mission to expand EarliPoint’s commercialization efforts and complete studies validating its efficacy for children up to seven years old. With continued investment and innovation, EarliTec is poised to transform the landscape of childhood diagnostics, ensuring that every child receives the support they need, when it matters most.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Upstage’s $72M Series B Funding Marks Milestone in AI Innovation

Upstage Co., Ltd., the South Korean AI powerhouse, is making waves in the tech world once again. With a recent $72 million injection in its Series B funding round, the company’s total investment now exceeds $100 million, solidifying its position as a trailblazer in AI software development.

Led by CEO Sung Kim, Upstage is on a mission to revolutionize work efficiency with its cutting-edge AI solutions. Their flagship product, Solar LLM, has garnered praise for its lightning-fast performance and unmatched cost-efficiency. By leveraging Depth-Up Scaling (DUS) technology, Solar delivers GPT-4-level performance, catering to the diverse needs of businesses across various industries.

But Upstage isn’t stopping there. The company’s Document AI solution, powered by state-of-the-art OCR technology, is transforming document processing for high-growth sectors like finance and healthcare. With clients including industry giants like Samsung and Hanwha, Upstage’s Document AI is streamlining workflows and reducing operational costs for businesses worldwide.

The Series B funding will fuel Upstage’s ambitious plans for global expansion, including the establishment of a new office in San Jose, California. This strategic move will enable Upstage to accelerate the development of purpose-trained LLMs tailored to the needs of global enterprises.

Leading the investment round are prominent backers such as SK Networks, KT, and Korea Development Bank, reaffirming their confidence in Upstage’s vision and capabilities. Existing investors, including SBVA and Primer Sazze Partners, have also doubled down on their support, recognizing Upstage’s potential to reshape the future of AI.

Founded in 2020, Upstage is committed to enhancing work efficiency through industry-leading document processing engines and LLMs. With Solar LLM and Document AI at the forefront of innovation, Upstage is poised to lead the AI revolution, one breakthrough at a time.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

dataplor Raises $10.6M Series A to Expand Global Location Intelligence

dataplor, a leading provider of global location intelligence solutions, has announced a successful Series A funding round. The round resulted in $10.6 million and was led by Spark Capital. This strategic investment underscores dataplor’s commitment to advancing its position as a premier source of international location data for enterprises worldwide.

With a vast database comprising over 300 million places across more than 200 countries and territories, dataplor stands at the forefront of delivering accurate and comprehensive location insights to businesses across various industries. From technology and logistics to consumer goods and finance, organizations rely on dataplor’s global coverage to drive informed decision-making and navigate complex market landscapes.

This funding round enables dataplor to further expand its worldwide coverage and enhance its suite of location intelligence solutions. By investing in product development and innovation, dataplor aims to provide its customers with even more robust and actionable insights to support their growth and expansion strategies.

dataplor’s innovative approach combines advanced technologies such as artificial intelligence and machine learning with a robust global infrastructure to gather, validate, and deliver location data with unparalleled precision. This ensures that customers receive timely and reliable information to support their expansion initiatives and strategic planning efforts.

In addition to enhancing its data coverage and product offerings, dataplor remains committed to maintaining the highest standards of data privacy and security. By adhering to ethical practices and stringent data protection measures, dataplor ensures that customers can leverage its solutions with confidence and trust.

As dataplor embarks on its next phase of growth and expansion, fueled by the Series A funding, it remains steadfast in its mission to empower businesses with actionable location intelligence, enabling them to unlock new opportunities and drive success on a global scale.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Nectar’s Sweet Success: Securing $40 Million Series B Funding

PerkCity, Inc. (DBA Nectar), the Utah-based culture platform specializing in employee recognition and rewards, has reached a significant milestone with the announcement of a committed $40 million Series B Funding Round. This funding, led by PeakSpan Capital, represents a pivotal moment for Nectar as it embarks on a journey of growth and expansion.

With this substantial investment, Nectar is poised to accelerate the development of its platform and suite of product services, focusing on enhancing workplace culture through recognition. The infusion of capital will enable Nectar to further innovate its core recognition products and introduce new strategic offerings designed to support organizations in building strong and engaged workplace cultures.

The Series B raise underscores Nectar’s commitment to empowering organizations worldwide to cultivate vibrant and inclusive environments where every individual feels valued and appreciated. By investing in research and development, Nectar aims to remain at the forefront of the industry, delivering impactful solutions to its growing client base.

The partnership with PeakSpan Capital provides Nectar with valuable resources and expertise to fuel its growth trajectory. With a focus on scalability, user experience, and innovation, Nectar is well-positioned to drive meaningful change in the workplace culture space.

The announcement of the Series B Funding marks a new chapter for Nectar, signaling its commitment to driving positive change in workplace culture worldwide. With a focus on innovation and growth, Nectar is poised to make a lasting impact on organizations and employees alike, shaping the future of work for years to come.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Teeing Up Success: Eastside Golf Secures $3.4M in Seed Funding

Eastside Golf, a burgeoning apparel company based in Wilmington, recently made waves in the industry with the announcement of a significant investment round totaling $3.4 million in seed funding. Led by Elysian Park Ventures (EPV) and PGA of America, this joint venture investment marks a pivotal moment for the company’s growth trajectory.

Founded in 2019 with a mission to promote diversity and youth engagement within the golfing community, Eastside Golf has quickly gained recognition for its innovative approach to sportswear. With a focus on inclusivity and style, the company has garnered attention from both consumers and industry insiders alike.

The infusion of capital from EPV and PGA of America comes at a crucial time for Eastside Golf, allowing the company to bolster its operational capacity and expand its apparel line. Key hires in wholesale management and product development signal the company’s commitment to strategic growth and scalability.

Recognizing the strategic value of its partnership with EPV and PGA of America, Eastside Golf aims to leverage their expertise and resources to drive exponential growth. With a solid foundation in place, the company is poised to capitalize on emerging opportunities in the market.

Looking ahead, Eastside Golf plans to launch a women’s apparel line, tapping into a new market segment while staying true to its core values of inclusivity and accessibility. Additionally, the company will expand its presence with new pop-up shops across the country, enhancing brand visibility and consumer engagement.

Beyond apparel, Eastside Golf is exploring new avenues for growth, including partnerships with athletes and celebrities to broaden its reach and influence. Community outreach initiatives and innovative product offerings further underscore the company’s commitment to driving positive change within the golfing community.

As Eastside Golf sets its sights on the future, the company remains dedicated to pushing the boundaries of traditional sportswear and redefining the golfing experience for a new generation of enthusiasts. With a strong foundation and strategic vision, Eastside Golf is poised to become a leading player in the industry.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Transforming Healthcare: Kilele Health’s Path to Impact

Kilele Health, a pioneering healthcare technology company, recently received a significant boost in funding for its mission to transform healthcare delivery. The company was awarded $1 million in funds from the National Science Foundation.

With a focus on leveraging technology to improve access to healthcare services, Kilele Health is poised to revolutionize the healthcare landscape. The recent funding injection will enable the company to further develop its cutting-edge solutions and expand its reach to underserved communities.

Founded on the principle of making healthcare more accessible and affordable for all, Kilele Health has been at the forefront of research and development in the healthcare technology sector. By harnessing the power of data analytics, artificial intelligence, and telemedicine, the company aims to bridge the gap between patients and healthcare providers.

One of the key areas of focus for Kilele Health is telemedicine, which has emerged as a vital tool in delivering healthcare services remotely. Through its innovative telemedicine platform, Kilele Health enables patients to consult with healthcare professionals from the comfort of their own homes, eliminating the need for costly and time-consuming visits to the doctor’s office.

In addition to telemedicine, Kilele Health is also working on solutions to improve healthcare delivery in rural and underserved areas. By developing mobile health clinics equipped with state-of-the-art medical technology, the company aims to bring essential healthcare services directly to communities that lack access to traditional healthcare facilities.

The $1 million in funding will play a crucial role in advancing Kilele Health’s research and development efforts. With this financial support, the company plans to enhance its existing technologies, develop new innovations, and scale its operations to reach more patients in need.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Empowering Caregivers: Cariloop’s Commitment to Growth and Impact

Cariloop, Inc., a Texas-based caregiver support platform, has raised $20 million during their Series C funding round. Led by ABS Capital and supported by existing investors such as KCRise Fund, the funding is expected to fuel Cariloop’s growth and expand its support solutions, while deepening its ties to communities like Kansas City.

Since its inception, Cariloop has been dedicated to helping families manage their loved ones’ care needs by providing an employer-sponsored, digitally-powered caregiver support platform. With a focus on reducing stress and burnout for caregivers, Cariloop’s comprehensive solution has resonated with corporate investors and companies in Kansas City, driving increased productivity and reduced absenteeism for employers.

Recognizing the significance of local support, Cariloop has made deliberate efforts to partner with Kansas City-based employers and expand its on-the-ground efforts to reach more companies and caregivers in the community. By fostering these partnerships and creating new employment opportunities, Cariloop aims to have a positive economic development impact in Kansas City.

The Series C investment will enable Cariloop to further expand its market reach with employers and caregivers, while also making key investments in its digital and concierge-level offerings. With nearly 75 percent of employees balancing work with caregiving responsibilities, there is a significant opportunity for Cariloop to provide critical support to one of the largest employee population groups.

Cariloop’s revenue growth of nearly 300 percent over the last three years is a testament to the effectiveness of its solutions, landing the company on prestigious lists such as the Inc. 5000 and Deloitte Technology Fast 500. By working with employers of all sizes and industries, Cariloop aims to relieve the stress and anxiety felt by all caregivers, regardless of their career path or geographical location.

As Cariloop continues to grow, it remains committed to fulfilling KCRise Fund’s early and continued expectations, while keeping its focus on attracting top talent from the Kansas City talent pool. By serving more companies and caregivers in the community, Cariloop is making a meaningful impact on the lives of caregivers and their families, one partnership at a time.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Revolutionizing Displays: NanoPattern’s Quantum Dot Ink Secures New Seed Funding

NanoPattern Technologies, Inc., led by cofounders Yu Kambe and Dmitri Talapin, has secured $1.5 million in a seed funding round. The funding will help to scale its photopatternable quantum dot ink, which enables the commercialization of next-generation displays.

The photopatternable quantum dot ink developed by NanoPattern is a game-changer for display component manufacturers. It facilitates the production of full-color microdisplays for a wide range of applications, including augmented reality, virtual reality, wearables, smartphones, tablets, and televisions.

This latest funding round follows a series of strategic investments, including support from the Polsky Center’s George Shultz Innovation Fund and grants from the National Science Foundation’s Small Business Innovation Research program. These investments have been instrumental in fueling NanoPattern’s research and development efforts, allowing the company to demonstrate the effectiveness and reliability of its quantum dot ink.

Partnering with Nanosys Shoei, the world’s largest quantum dot manufacturer, NanoPattern has successfully showcased sub-10 micron pixel resolution, paving the way for widespread adoption of its technology. With the new funding, the company plans to transition from product demonstration to showcasing product-specific features while enhancing quantity control and manufacturing capabilities.

Expansion into a cleanroom environment is also on the agenda for NanoPattern, highlighting the company’s commitment to maintaining rigorous quality standards. Leveraging the advantages of the Chicago area ecosystem, including access to cleanrooms and top talent from local universities, NanoPattern is poised for further growth and innovation.

The successful seed round, led by Queen City Angels and supported by other prominent investors, is a testament to NanoPattern’s potential to disrupt the display industry. With plans to expand its team and attract top talent to the Midwest, NanoPattern is poised to lead the charge in advancing display technology and driving innovation in the region.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Gaining Ground: Arbutus Biopharma and Genevant Sciences in Patent Battle with Moderna

In the ongoing saga of patent disputes surrounding COVID-19 vaccines, Arbutus Biopharma Corporation and Genevant Sciences have made strides in their legal battle against Moderna. With a recent court order clarifying key terms of the patents in question, the two companies are making strides in their quest to claim their share of the profits from Moderna’s Spikevax vaccine.

Arbutus and Genevant initially asserted their patents in 2022, alleging that Moderna utilized their groundbreaking lipid nanoparticle (LNP) delivery platform without proper compensation or licensing. Now, with a joint claim construction brief filed and a detailed court order dissecting the language and scientific intricacies of the patents, the plaintiffs are bolstering their case against Moderna.

Judge Mitchell S. Goldberg’s order largely favors Arbutus and Genevant, rejecting many of Moderna’s proposed constructions and strengthening the plaintiffs’ position. The companies seek compensation for their patented technology, which they argue played a crucial role in the success of Moderna’s COVID-19 vaccine.

While Moderna maintains that its Spikevax technology is the result of independent research and development, Arbutus and Genevant remain steadfast in their commitment to protecting their intellectual property. Interim CEO Michael J. McElhaugh expressed satisfaction with the court’s rulings and emphasized the importance of defending their patents.

The legal battle between the parties is expected to continue for at least two more years, with both sides gearing up for trial. Moderna faces similar lawsuits from other biopharmaceutical companies, underscoring the complexity of intellectual property disputes in the pharmaceutical industry.

Despite the financial success of Spikevax in previous years, sales have been impacted by waning demand and competition from newer boosters. Nevertheless, Arbutus and Genevant’s pursuit of fair compensation for their patented technology remains unwavering.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.